B
BIA Separations
Biotech & Life Sciences · Wilmington, United States · Founded 1998
A worldwide provider of solutions for biopharmaceutical companies MoreLess
BIA Separations specializes in the development and manufacturing of Convective Interaction Media (CIM) monolithic chromatographic columns, which are essential for the production, purification, and analytics of large biomolecules. The company serves clients in the biopharmaceutical industry, including those involved in gene therapy, vaccine production, and mRNA technologies. Operating in the biotechnology market, BIA Separations employs a business model that focuses on selling high-performance chromatography tools and providing technical support and process development services. Revenue is generated through the direct sale of their proprietary monolithic columns and associated services. The company has been integrated into Sartorius, enhancing its portfolio in gene therapy and vaccine solutions.
Keywords: monolithic columns, chromatography, biopharmaceuticals, gene therapy, vaccine production, mRNA technologies, biomolecule purification, biotechnology, process development, technical support.
Talent graph
BIA Separations's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on BIA Separations's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where BIA Separations has talent and traffic
team presence
across markets
Market sentiment
What the market is saying about BIA Separations
An AI-synthesized read of the highest-engagement posts about BIA Separations on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BIA Separations on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.